Intel (INTC) 10-Q 27 Oct 23 2023 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares shares in Millions	9 Months Ended
	Sep. 30, 2023	Oct. 20, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Entity File Number	000-06217
Entity Registrant Name	INTEL CORPORATION
Entity Central Index Key	0000050863
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-1672743
Entity Address, Address Line One	2200 Mission College Boulevard,
Entity Address, City or Town	Santa Clara,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95054-1549
City Area Code	(408)
Local Phone Number	765-8080
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	INTC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,216

Consolidated Condensed Statemen

Consolidated Condensed Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022	Sep. 30, 2023	Oct. 01, 2022
Income Statement [Abstract]
Net revenue	$ 14,158	$ 15,338	$ 38,822	$ 49,012
Cost of sales	8,140	8,803	24,158	27,646
Gross margin	6,018	6,535	14,664	21,366
Research and development	3,870	4,302	12,059	13,064
Marketing, general, and administrative	1,340	1,744	4,017	5,296
Restructuring and other charges	816	664	1,080	(460)
Operating expenses	6,026	6,710	17,156	17,900
Operating income (loss)	(8)	(175)	(2,492)	3,466
Gains (losses) on equity investments, net	(191)	(151)	(46)	4,082
Interest and other, net	147	138	512	1,016
Income (loss) before taxes	(52)	(188)	(2,026)	8,564
Provision for (benefit from) taxes	(362)	(1,207)	(1,041)	(114)
Net income (loss)	310	1,019	(985)	8,678
Less: Net income (loss) attributable to non-controlling interests	13	0	(5)	0
Net income (loss) attributable to Intel	$ 297	$ 1,019	$ (980)	$ 8,678
Earnings per share - Basic (in dollars per share)	$ 0.07	$ 0.25	$ (0.23)	$ 2.11
Earnings per share - Diluted (in dollars per share)	$ 0.07	$ 0.25	$ (0.23)	$ 2.10
Weighted average shares of common stock outstanding:
Basic (shares)	4,202	4,118	4,180	4,104
Diluted (shares)	4,229	4,125	4,180	4,123

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022	Sep. 30, 2023	Oct. 01, 2022
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 310	$ 1,019	$ (985)	$ 8,678
Changes in other comprehensive income, net of tax:
Net unrealized holding gains (losses) on derivatives	(320)	(436)	(310)	(1,178)
Actuarial valuation and other pension benefits (expenses), net	2	10	5	37
Translation adjustments and other	1	0	6	(30)
Other comprehensive income (loss)	(317)	(426)	(299)	(1,171)
Total comprehensive income (loss)	(7)	593	(1,284)	7,507
Less: comprehensive income (loss) attributable to non-controlling interests	13	0	(5)	0
Total comprehensive income (loss)	$ (20)	$ 593	$ (1,279)	$ 7,507

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 7,621	$ 11,144
Short-term investments	17,409	17,194
Accounts receivable, net	2,843	4,133
Inventories	11,466	13,224
Other current assets	4,472	4,712
Total current assets	43,811	50,407
Property, plant, and equipment, net of accumulated depreciation of $97,122 ($93,386 as of December 31, 2022)	93,352	80,860
Equity Investments	5,700	5,912
Goodwill	27,591	27,591
Identified intangible assets, net	4,970	6,018
Other long-term assets	13,413	11,315
Total assets	188,837	182,103
Current liabilities:
Short-term debt	2,288	4,367
Accounts payable	8,669	9,595
Accrued compensation and benefits	3,115	4,084
Income taxes payable	2,112	2,251
Other accrued liabilities	12,430	11,858
Total current liabilities	28,614	32,155
Debt	46,591	37,684
Other long-term liabilities	7,946	8,978
Contingencies (Note 13)
Stockholders’ equity:
Common stock and capital in excess of par value, 4,216 issued and outstanding (4,137 issued and outstanding as of December 31, 2022)	35,653	31,580
Accumulated other comprehensive income (loss)	(861)	(562)
Retained earnings	67,021	70,405
Total stockholders' equity	101,813	101,423
Non-controlling interest	3,873	1,863
Accumulated other comprehensive income (loss)	105,686	103,286
Total liabilities and stockholders’ equity	$ 188,837	$ 182,103

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) shares in Millions, $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Assets
Accumulated depreciation	$ 97,122	$ 93,386
Stockholders’ equity:
Common stock, shares issued	4,216	4,137
Common stock, shares outstanding	4,216	4,137

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022
Statement of Cash Flows [Abstract]
Cash and cash equivalents, beginning of period	$ 11,144	$ 4,827
Cash flows provided by (used for) operating activities:
Net income (loss)	(985)	8,678
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation	5,753	8,309
Share-based compensation	2,433	2,392
Restructuring and other charges	718	665
Amortization of intangibles	1,336	1,439
(Gains) losses on equity investments, net	47	(4,075)
(Gains) losses on divestitures	0	(1,072)
Changes in assets and liabilities:
Accounts receivable	1,290	1,991
Inventories	1,758	(2,043)
Accounts payable	(1,082)	(485)
Accrued compensation and benefits	(1,171)	(1,912)
Income taxes	(2,676)	(4,062)
Other assets and liabilities	(574)	(2,095)
Total adjustments	7,832	(948)
Net cash provided by operating activities	6,847	7,730
Cash flows provided by (used for) investing activities:
Additions to property, plant and equipment	(19,054)	(19,145)
Purchases of short-term investments	(37,287)	(31,669)
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale	36,725	35,129
Sales of equity investments	375	4,880
Proceeds from divestiture	0	6,579
Other investing	518	(2,764)
Net cash used for investing activities	(18,723)	(6,990)
Cash flows provided by (used for) financing activities:
Repayment of commercial paper	(3,944)	0
Payments on finance leases	(96)	(341)
Partner contributions	1,106	0
Proceeds from sales of subsidiary shares	2,423	0
Issuance of long-term debt, net of issuance costs	11,391	6,103
Repayment of debt	(423)	(3,088)
Payment of dividends to stockholders	(2,561)	(4,488)
Other financing	457	776
Net cash provided by (used for) financing activities	8,353	(1,038)
Net increase (decrease) in cash and cash equivalents	(3,523)	(298)
Cash and cash equivalents, end of period	7,621	4,529
Supplemental disclosures:
Acquisition of property, plant, and equipment included in accounts payable and accrued liabilities	5,234	3,386
Interest, net of capitalized interest	968	315
Income taxes, net of refunds	$ 1,649	$ 3,960

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Common Stock and Capital in Excess of Par Value	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Noncontrolling Interest
Common stock, shares outstanding, beginning (in shares) at Dec. 25, 2021		4,070
Total stockholders' equity, beginning at Dec. 25, 2021	$ 95,391	$ 28,006	$ (880)	$ 68,265	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	8,678			8,678
Other comprehensive income (loss)	(1,171)		(1,171)
Employee equity incentive plans and other (in shares)		66
Employee equity incentive plans and other	1,000	$ 1,000
Share-based compensation	2,392	$ 2,392
Restricted stock unit withholdings (in shares)		(9)
Restricted stock unit withholdings	(407)	$ (486)		79
Cash dividends declared	(5,998)			(5,998)
Common stock, shares outstanding, ending (in shares) at Oct. 01, 2022		4,127
Total stockholders' equity, ending at Oct. 01, 2022	99,885	$ 30,912	(2,051)	71,024	0
Common stock, shares outstanding, beginning (in shares) at Jul. 02, 2022		4,106
Total stockholders' equity, beginning at Jul. 02, 2022	101,218	$ 29,858	(1,625)	72,985	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	1,019			1,019
Other comprehensive income (loss)	(426)		(426)
Employee equity incentive plans and other (in shares)		24
Employee equity incentive plans and other	399	$ 399
Share-based compensation	793	$ 793
Restricted stock unit withholdings (in shares)		(3)
Restricted stock unit withholdings	(106)	$ (138)		32
Cash dividends declared	(3,012)			(3,012)
Common stock, shares outstanding, ending (in shares) at Oct. 01, 2022		4,127
Total stockholders' equity, ending at Oct. 01, 2022	$ 99,885	$ 30,912	(2,051)	71,024	0
Common stock, shares outstanding, beginning (in shares) at Dec. 31, 2022	4,137	4,137
Total stockholders' equity, beginning at Dec. 31, 2022	$ 103,286	$ 31,580	(562)	70,405	1,863
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(985)			(980)	(5)
Other comprehensive income (loss)	(299)		(299)
Net proceeds from sales of subsidiary shares and partner contributions	3,166	$ 1,254			1,912
Employee equity incentive plans and other (in shares)		91
Employee equity incentive plans and other	1,037	$ 1,037
Share-based compensation	2,433	$ 2,330			103
Restricted stock unit withholdings (in shares)		(12)
Restricted stock unit withholdings	(391)	$ (548)		157
Cash dividends declared	$ (2,561)			(2,561)
Common stock, shares outstanding, ending (in shares) at Sep. 30, 2023	4,216	4,216
Total stockholders' equity, ending at Sep. 30, 2023	$ 105,686	$ 35,653	(861)	67,021	3,873
Common stock, shares outstanding, beginning (in shares) at Jul. 01, 2023		4,188
Total stockholders' equity, beginning at Jul. 01, 2023	104,471	$ 34,330	(544)	67,231	3,454
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	310			297	13
Other comprehensive income (loss)	(317)		(317)
Net proceeds from sales of subsidiary shares and partner contributions	759	$ 388			371
Employee equity incentive plans and other (in shares)		33
Employee equity incentive plans and other	372	$ 372
Share-based compensation	772	$ 737			35
Restricted stock unit withholdings (in shares)		(5)
Restricted stock unit withholdings	(156)	$ (174)		18
Cash dividends declared	$ (525)			(525)
Common stock, shares outstanding, ending (in shares) at Sep. 30, 2023	4,216	4,216
Total stockholders' equity, ending at Sep. 30, 2023	$ 105,686	$ 35,653	$ (861)	$ 67,021	$ 3,873

Consolidated Condensed Statem_5

Consolidated Condensed Statements of Stockholders' Equity (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022	Sep. 30, 2023	Oct. 01, 2022
Retained Earnings
Cash dividends declared (in dollars per share)	$ 0.13	$ 0.73	$ 0.62	$ 1.46

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Note 1 : Basis of Presentation We prepared our interim Consolidated Condensed Financial Statements that accompany these notes in conformity with US GAAP, consistent in all material respects with those applied in our 2022 Form 10-K. We have a 52- or 53-week fiscal year that ends on the last Saturday in December. Fiscal year 2023 is a 52-week fiscal year; fiscal 2022 was a 53-week fiscal year, with the extra week included in the first quarter of 2022. We have made estimates and judgments affecting the amounts reported in our Consolidated Condensed Financial Statements and the accompanying notes. The actual results that we experience may differ materially from our estimates. The interim financial information is unaudited, and reflects all normal adjustments that are, in our opinion, necessary to provide a fair statement of results for the interim periods presented. This report should be read in conjunction with the Consolidated Financial Statements in our 2022 Form 10-K where we include additional information on our critical accounting estimates, policies, and the methods and assumptions used in our estimates.

Operating Segments

Operating Segments	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Operating Segments	Note 2 : Operating Segments We previously announced the organizational change to integrate AXG into CCG and DCAI. This change is intended to drive a more effective go-to-market capability and to accelerate the scale of these businesses, while also reducing costs. As a result, we modified our segment reporting in the first quarter of 2023 to align to this and certain other business reorganizations. All prior-period segment data has been retrospectively adjusted to reflect the way our CODM internally receives information and manages and monitors our operating segment performance starting in fiscal year 2023. We manage our business through the following operating segments: ▪ Client Computing (CCG) ▪ Data Center and AI (DCAI) ▪ Network and Edge (NEX) ▪ Mobileye ▪ Intel Foundry Services (IFS) We derive a substantial majority of our revenue from our principal products that incorporate various components and technologies, including a microprocessor and chipset, a stand-alone SoC, or a multichip package, which is based on Intel ® architecture. CCG, DCAI and NEX are our reportable operating segments. Mobileye and IFS do not qualify as reportable operating segments; however, we have elected to disclose the results of these non-reportable operating segments. When we enter into federal contracts, they are aligned to the sponsoring operating segment. We have sales and marketing, manufacturing, engineering, finance, and administration groups. Expenses for these groups are generally allocated to the operating segments. We have an "all other" category that includes revenue, expenses, and charges such as: ▪ results of operations from non-reportable segments not otherwise presented, and from start-up businesses that support our initiatives; ▪ historical results of operations from divested businesses; ▪ amounts included within restructuring and other charges ; ▪ employee benefits, compensation, impairment charges, and other expenses not allocated to the operating segments; and ▪ acquisition-related costs, including amortization and any impairment of acquisition-related intangibles and goodwill. The CODM, who is our CEO, allocates resources to and assesses the performance of each operating segment using information about the operating segment's revenue and operating income (loss). The CODM does not evaluate operating segments using discrete asset information, and we do not identify or allocate assets by operating segments. Based on the interchangeable nature of our manufacturing and assembly and test assets, most of the related depreciation expense is not directly identifiable within our operating segments, as it is included in overhead cost pools and subsequently absorbed into inventory as each product passes through our manufacturing process. Because our products are then sold across multiple operating segments, it is impracticable to determine the total depreciation expense included as a component of each operating segment's operating income (loss) results. We do not allocate gains and losses from equity investments, interest and other income, share-based compensation, or taxes to our operating segments. Although the CODM uses operating income (loss) to evaluate the segments, operating costs included in one segment may benefit other segments. The accounting policies for segment reporting are the same as for Intel as a whole. There have been no changes to our segment accounting policies disclosed in our 2022 Form 10-K except for the organizational change described above. Net revenue and operating income (loss) for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Net revenue: Client Computing Desktop $ 2,753 $ 3,222 $ 7,002 $ 8,152 Notebook 4,503 4,408 11,806 15,118 Other 611 498 1,606 1,858 7,867 8,128 20,414 25,128 Data Center and AI 3,814 4,255 11,536 15,024 Network and Edge 1,450 2,133 4,303 6,483 Mobileye 530 450 1,442 1,304 Intel Foundry Services 311 78 661 291 All other 186 294 466 782 Total net revenue $ 14,158 $ 15,338 $ 38,822 $ 49,012 Operating income (loss): Client Computing $ 2,073 $ 1,447 $ 3,632 $ 5,045 Data Center and AI 71 (139) (608) 1,174 Network and Edge 17 197 (470) 907 Mobileye 170 142 422 480 Intel Foundry Services (86) (90) (369) (247) All other (2,253) (1,732) (5,099) (3,893) Total operating income (loss) $ (8) $ (175) $ (2,492) $ 3,466 In the second quarter of 2022, we initiated the wind-down of our Intel® Optane™ memory business, which is part of our DCAI operating segment, resulting in an inventory impairment of $559 million in Cost of sales

Non-Controlling Interests

Non-Controlling Interests	9 Months Ended
	Sep. 30, 2023
Noncontrolling Interest [Abstract]
Non-Controlling Interests	Note 3 : Non-Controlling Interests Semiconductor Co-Investment Program In 2022, we closed a transaction with Brookfield Asset Management (Brookfield) resulting in the formation of Arizona Fab LLC (Arizona Fab), a VIE for which we and Brookfield own 51% and 49%, respectively. Because we are the primary beneficiary of the VIE, we fully consolidate the results of Arizona Fab into our consolidated financial statements. Generally, contributions will be made to, and distributions will be received from, Arizona Fab based on both parties' proportional ownership. We will be sole operator and majority owner of two new chip factories that will be constructed by Arizona Fab, and we will have the right to purchase 100% of the related factory output. Once production commences, we will be required to operate Arizona Fab at minimum production levels measured in wafer starts per week and will be required to limit excess inventory held on site or we will be subject to certain penalties. We have an unrecognized commitment to fund our respective share of the total construction costs of Arizona Fab of $29.0 billion. As of September 30, 2023, a substantial majority of the assets of Arizona Fab consisted of property, plant, and equipment. The assets held by Arizona Fab, which can be used only to settle obligations of the VIE and are not available to us, were $4.0 billion as of September 30, 2023 ($1.8 billion as of December 31, 2022). Non-controlling interest in Arizona Fab was $2.0 billion as of September 30, 2023 ($874 million as of December 31, 2022). Net loss attributable to non-controlling interest in Arizona Fab was $3 million in the third quarter of 2023 and $12 million in the first nine months of 2023; there was no net income (loss) attributable to non-controlling interest in the first nine months of 2022. Mobileye In 2022, Mobileye completed its IPO and certain other equity financing transactions that resulted in net proceeds of $1.0 billion. During the second quarter of 2023, we converted $38.5 million of Class B shares into Class A shares, representing 5% of Mobileye’s outstanding capital stock, and subsequently sold the Class A shares for $42 per share as part of a secondary offering. We received net proceeds of $1.6 billion and increased our capital in excess of par value by $663 million, net of tax, as a result of the secondary offering. We continue to consolidate the results of Mobileye into our consolidated financial statements. As of September 30, 2023, Intel held approximately 88% (94% as of December 31, 2022) of the outstanding equity interest in Mobileye. Non-controlling interest in Mobileye was $1.8 billion as of September 30, 2023 ($1.0 billion as of December 31, 2022). Net income attributable to non-controlling interest in Mobileye was $6 million in the third quarter of 2023 and $3 million of net loss in the first nine months of 2023; there was no net income (loss) attributable to non-controlling interest in the first nine months of 2022. IMS Nanofabrication In August 2023, we closed an agreement to sell a 20% minority stake in our IMS Nanofabrication GmbH (IMS) business, a business within our IFS operating segment, to Bain Capital Special Situations (Bain Capital). Net proceeds resulting from the sale were $849 million and our capital in excess of par value increased by $591 million, net of tax. We continue to consolidate the results of IMS into our consolidated financial statements. Non-controlling interest in IMS was $109 million as of September 30, 2023. Net income attributable to the non-controlling interest in IMS was $10 million in the third quarter of 2023 and in the first nine months of 2023.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Earnings Per Share	Note 4 : Earnings (Loss) Per Share We computed basic earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding during the period. We computed diluted earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding plus potentially dilutive shares of common stock outstanding during the period. Three Months Ended Nine Months Ended (In Millions, Except Per Share Amounts) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Net income (loss) $ 310 $ 1,019 $ (985) $ 8,678 Less: Net income (loss) attributable to non-controlling interests 13 — (5) — Net income (loss) attributable to Intel 297 1,019 (980) 8,678 Weighted average shares of common stock outstanding—basic 4,202 4,118 4,180 4,104 Dilutive effect of employee equity incentive plans 27 7 — 19 Weighted average shares of common stock outstanding—diluted 4,229 4,125 4,180 4,123 Earnings (loss) per share attributable to Intel—basic $ 0.07 $ 0.25 $ (0.23) $ 2.11 Earnings (loss) per share attributable to Intel—diluted $ 0.07 $ 0.25 $ (0.23) $ 2.10 Potentially dilutive shares of common stock from employee equity incentive plans are determined by applying the treasury stock method to the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan. Securities that were anti-dilutive were insignificant and were excluded from the computation of diluted earnings per share in all periods presented. Due to our net loss in the nine months ended September 30, 2023, the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan had an anti-dilutive effect on diluted loss per share for the period and were excluded.

Other Financial Statement Detai

Other Financial Statement Details	9 Months Ended
	Sep. 30, 2023
Other Financial Statement Details [Abstract]
Other Financial Statement Details	Note 5 : Other Financial Statement Details Accounts Receivable We sell certain of our accounts receivable on a non-recourse basis to third-party financial institutions. We record these transactions as sales of receivables and present cash proceeds as cash provided by operating activities in the Consolidated Condensed Statements of Cash Flows. Accounts receivable sold under non-recourse factoring arrangements were $1.5 billion during the first nine months of 2023. After the sale of our accounts receivable, we expect to collect payment from the customers and remit it to the third-party financial institution. Inventories (In Millions) Sep 30, 2023 Dec 31, 2022 Raw materials $ 1,278 $ 1,517 Work in process 6,266 7,565 Finished goods 3,922 4,142 Total inventories $ 11,466 $ 13,224 Property, Plant, and Equipment Effective January 2023, we increased the estimated useful life of certain production machinery and equipment from 5 years to 8 years. We estimate this change resulted in an approximate $690 million increase to gross margin and an approximate $110 million decrease in R&D expense in the third quarter of 2023 when compared to what the impact would have been using the estimated useful life in place prior to this change. We estimate this change resulted in an approximate $1.6 billion increase to gross margin and an approximate $320 million decrease in R&D expenses in the first nine months of 2023. As of September 30, 2023, we estimate this change resulted in an approximate $1.2 billion decrease in ending inventory values. These estimates are based on the assets in use and under construction as of the beginning of 2023. Other Accrued Liabilities Other accrued liabilities include deferred compensation of $2.6 billion as of September 30, 2023 ($2.4 billion as of December 31, 2022). Interest and Other, Net Three Months Ended Nine Months Ended (In Millions) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Interest income $ 332 $ 170 $ 979 $ 315 Interest expense (204) (114) (611) (347) Other, net 19 82 144 1,048 Total interest and other, net $ 147 $ 138 $ 512 $ 1,016 Interest expense is net of $395 million of interest capitalized in the third quarter of 2023 and $1.1 billion in the first nine months of 2023 ($220 million in the third quarter of 2022 and $516 million in the first nine months of 2022). Other, net includes a gain in 2022 of $1.0 billion resulting from the first closing of the divestiture of our NAND memory business.

Restructuring and Other Charges

Restructuring and Other Charges	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring and Other Charges	Note 6 : Restructuring and Other Charges Three Months Ended Nine Months Ended (In Millions) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Employee severance and benefit arrangements $ 59 $ 607 $ 191 $ 650 Litigation charges and other 757 4 854 (1,199) Asset impairment charges — 53 35 89 Total restructuring and other charges $ 816 $ 664 $ 1,080 $ (460) The 2022 Restructuring Program was approved in the third quarter of 2022 to rebalance our workforce and operations to create efficiencies and improve our product execution in alignment with our strategy. We expect these actions to be substantially completed by the end of 2023, but this is subject to change. Any changes to the estimates or timing of executing the 2022 Restructuring Program will be reflected in our results of operations. Restructuring activity for the 2022 Restructuring Program during the first nine months of 2023 was as follows: (In Millions) Accrued restructuring balance as of December 31, 2022 $ 873 Additional accruals 130 Adjustments 56 Cash payments (923) Accrued restructuring balance as of September 30, 2023 $ 136 The accrued restructuring balances as of September 30, 2023 and December 31, 2022 were recorded as current liabilities within accrued compensation and benefits on the Consolidated Condensed Balance Sheets . The cumulative cost of the 2022 Restructuring Program as of September 30, 2023 was $1.2 billion. Litigation charges and other includes a $401 million charge in the third quarter of 2023 for an EC-imposed fine. In 2009, we recorded and paid an EC fine that was subsequently annulled, resulting in a benefit of $1.2 billion in t he first quarter of 2022. Refer to "Note 13: Contingencies" within the Notes to Consolidated Condensed Financial Statements for further information on legal proceedings related to the EC fine. Also in the third quarter of 2023 we m utually agreed with Tower to terminate the agreement we entered into during the first quarter of 2022 to acquire Tower in a cash-for-stock transaction, representing a total enterprise value of approximately $5.4 billion as of the agreement date. We mutually agreed to terminate the agreement due to our inability to obtain required regulatory approvals in a timely manner and we paid a termination fee in accordance with the terms of the agreement, resulting in a $353 million charge included in Litigation charges and other .

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 7 : Income Taxes Three Months Ended Nine Months Ended (In Millions) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Income (loss) before taxes $ (52) $ (188) $ (2,026) $ 8,564 Provision for (benefit from) taxes $ (362) $ (1,207) $ (1,041) $ (114) Effective tax rate 696.2 % 642.0 % 51.4 % (1.3) % Our provision for, or benefit from, income taxes for an interim period has historically been determined using an estimated annual effective tax rate, adjusted for discrete items, if any. Under certain circumstances where we are unable to make a reliable estimate of the annual effective tax rate, we use the actual effective tax rate for the year-to-date period. During the first nine months of 2023, we used this approach due to the variability of the rate as a result of fluctuations in forecasted income and the effects of being taxed in multiple tax jurisdictions.

Investments

Investments	9 Months Ended
	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Investments	Note 8 : Investments Short-term Investments Short-term investments include marketable debt investments in corporate debt, government debt, and financial institution instruments, and are recorded within cash and cash equivalents and short-term investments on the Consolidated Condensed Balance Sheets . Government debt includes instruments such as non-US government bills and bonds and US agency securities. Financial institution instruments include instruments issued or managed by financial institutions in various forms, such as commercial paper, fixed- and floating-rate bonds, money market fund deposits, and time deposits. As of September 30, 2023, and December 31, 2022, substantially all time deposits were issued by institutions outside the US. For certain of our marketable debt investments, we economically hedge market risks at inception with a related derivative instrument or the marketable debt investment itself is used to economically hedge currency exchange rate risk from remeasurement. These hedged investments are reported at fair value with gains or losses from the investments and the related derivative instruments recorded in interest and other, net . The fair value of our hedged investments was $16.1 billion as of September 30, 2023 ($16.2 billion as of December 31, 2022). For hedged investments still held at the reporting date, we recorded net losses of $329 million in the third quarter of 2023 and net losses of $336 million in the first nine months of 2023 ($861 million of net losses in the third quarter of 2022 and $1.8 billion of net losses in the first nine months of 2022). We recorded net gains on the related derivatives of $320 million in the third quarter of 2023 and net gains of $354 million in the first nine months of 2023 ($916 million of net gains in the third quarter of 2022 and net gains of $1.8 billion in the first nine months of 2022). Our remaining unhedged marketable debt investments are reported at fair value, with unrealized gains or losses, net of tax, recorded in accumulated other comprehensive income (loss) . The adjusted cost of our unhedged investments was $6.1 billion as of September 30, 2023 ($10.2 billion as of December 31, 2022), which approximated the fair value for these periods. The fair value of marketable debt investments, by contractual maturity, as of September 30, 2023, was as follows: (In Millions) Fair Value Due in 1 year or less $ 11,487 Due in 1–2 years 2,249 Due in 2–5 years 6,220 Due after 5 years 417 Instruments not due at a single maturity date 1 1,814 Total $ 22,187 1 Instruments not due at a single maturity date is comprised of money market fund deposits, which are classified as either short-term investments or cash and cash equivalents. Equity Investments (In Millions) Sep 30, 2023 Dec 31, 2022 Marketable equity securities 1 $ 1,117 $ 1,341 Non-marketable equity securities 4,578 4,561 Equity method investments 5 10 Total $ 5,700 $ 5,912 1 Over 90% of our marketable equity securities are subject to trading-volume or market-based restrictions, which limit the number of shares we may sell in a specified period of time, impacting our ability to liquidate these investments. The trading volume restrictions generally apply for as long as we own more than 1% of the outstanding shares. Market-based restrictions result from the rules of the respective exchange. The components of gains (losses) on equity investments, net for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Ongoing mark-to-market adjustments on marketable equity securities $ (267) $ (244) $ (164) $ (883) Observable price adjustments on non-marketable equity securities 7 67 17 273 Impairment charges (53) (45) (127) (112) Sale of equity investments and other 1 122 71 228 4,804 Total gains (losses) on equity investments, net $ (191) $ (151) $ (46) $ 4,082 1 Sale of equity investments and other includes initial fair value adjustments recorded upon a security becoming marketable, realized gains (losses) on sales of non-marketable equity investments and equity method investments, and our share of equity method investee gains (losses) and distributions. Net unrealized gains and losses for our marketable and non-marketable equity securities for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Net unrealized gains (losses) recognized during the period on equity securities $ (205) $ (154) $ (64) $ (490) Less: Net (gains) losses recognized during the period on equity securities sold during the period 12 1 (15) 15 Net unrealized gains (losses) recognized during the reporting period on equity securities still held at the reporting date $ (193) $ (153) $ (79) $ (475) McAfee Corp.

Acquisitions and Divestitures

Acquisitions and Divestitures	9 Months Ended
	Sep. 30, 2023
Business Combinations [Abstract]
Acquisitions and Divestitures	Note 9 : Divestitures NAND Memory Business On December 29, 2021, we closed the first phase of our agreement with SK hynix Inc. (SK hynix) to divest our NAND memory business for $9.0 billion in cash. Our NAND memory business includes our NAND memory technology and manufacturing business (the NAND OpCo Business), of which we deconsolidated our ongoing interests as part of the sale . The transaction will be completed in two closings and upon the first closing in the first quarter of 2022, SK hynix paid $7.0 billion of consideration and we recognized a pre-tax gain of $1.0 billion within interest and other, net , and tax expense of $495 million. We recorded a receivable in other long-term assets for the remaining proceeds of $1.9 billion which remains outstanding as of September 30, 2023, and will be received upon the second closing of the transaction, expected to be no earlier than March 2025. The wafer manufacturing and sale agreement includes incentives and penalties that are contingent on the cost of operation and output of the NAND OpCo Business. These incentives and penalties present a maximum exposure of up to $500 million annually, and $1.5 billion in the aggregate. We are currently in negotiations with SK hynix to update the operating plan of the NAND OpCo Business in light of the current business environment and projections, which may impact the metrics associated with the incentives and penalties and our expectations of the performance of the NAND OpCo Business against those metrics. As of September 30, 2023, we also have a receivable due from the NAND OpCo Business, a deconsolidated entity, of $204 million recorded within other current assets

Borrowings

Borrowings	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Borrowings	Note 10 : Borrowings In the third quarter of 2023, we remarketed $423 million aggregate principal amount of bonds issued by the Industrial Development Authority of the City of Chandler, Arizona (the Arizona bonds) and the State of Oregon Business Development Commission (the Oregon bonds). The bonds are unsecured general obligations in accordance with loan agreements we entered into with each of the Industrial Development Authority of the City of Chandler, Arizona and the State of Oregon Business Development Commission. The bonds mature in 2035 and 2040 and have 3.8% and 4.1% coupons. Both the Arizona and Oregon bonds are subject to optional tender starting in February 2028 and mandatory tender in June 2028, at which time we may remarket the bonds for a new term period. In the first quarter of 2023, we issued a total of $11.0 billion aggregate principal amount of senior notes. We also amended both our 5-year $5.0 billion revolving credit facility agreement, extending the maturity date by one year to March 2028, and our 364-day $5.0 billion credit facility agreement, extending the maturity date to March 2024. The revolving credit facilities had no borrowings outstanding as of September 30, 2023. We have an ongoing authorization from our Board of Directors to borrow up to $10.0 billion under our commercial paper program. In the first nine months of 2023, we settled in cash $3.9 billion of our commercial paper. We had no outstanding commercial paper as of September 30, 2023 ($3.9 billion as of December 31, 2022). Our senior fixed rate notes pay interest semiannually. We may redeem the fixed rate notes prior to their maturity at our option at specified redemption prices and subject to certain restrictions. The obligations under our senior fixed rate notes rank equally in the right of payment with all of our other existing and future senior unsecured indebtedness and effectively rank junior to all liabilities of our subsidiaries.

Fair Value

Fair Value	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value	Note 11 : Fair Value Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis Sep 30, 2023 Dec 31, 2022 Fair Value Measured and Recorded at Reporting Date Using Fair Value Measured and Recorded at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Cash equivalents: Corporate debt $ — $ 1,074 $ — $ 1,074 $ — $ 856 $ — $ 856 Financial institution instruments¹ 1,779 1,876 — 3,655 6,899 1,474 — 8,373 Government debt² — 49 — 49 — — — — Reverse repurchase agreements — 2,334 — 2,334 — 1,301 — 1,301 Short-term investments: Corporate debt — 6,168 — 6,168 — 5,381 — 5,381 Financial institution instruments¹ 35 4,105 — 4,140 196 4,729 — 4,925 Government debt² 50 7,051 — 7,101 48 6,840 — 6,888 Other current assets: Derivative assets 131 1,013 — 1,144 — 1,264 — 1,264 Loans receivable — 53 — 53 — 53 — 53 Marketable equity securities 1,117 — — 1,117 1,341 — — 1,341 Other long-term assets: Derivative assets — 1 — 1 — 10 — 10 Total assets measured and recorded at fair value $ 3,112 $ 23,724 $ — $ 26,836 $ 8,484 $ 21,908 $ — $ 30,392 Liabilities Other accrued liabilities: Derivative liabilities $ 17 $ 727 $ 147 $ 891 $ 111 $ 485 $ 89 $ 685 Other long-term liabilities: Derivative liabilities — 841 — 841 — 699 — 699 Total liabilities measured and recorded at fair value $ 17 $ 1,568 $ 147 $ 1,732 $ 111 $ 1,184 $ 89 $ 1,384 1 Level 1 investments consist of money market funds. Level 2 investments consist primarily of certificates of deposit, time deposits, and notes and bonds issued by financial institutions. 2 Level 1 investments consist primarily of US Treasury securities. Level 2 investments consist primarily of non-US government debt. Assets Measured and Recorded at Fair Value on a Non-Recurring Basis Our non-marketable equity securities, equity method investments, and certain non-financial assets, such as intangible assets and property, plant, and equipment, are recorded at fair value only if an impairment or observable price adjustment is recognized in the current period. If an observable price adjustment or impairment is recognized on our non-marketable equity securities during the period, we classify these assets as Level 3. Financial Instruments Not Recorded at Fair Value on a Recurring Basis Financial instruments not recorded at fair value on a recurring basis include non-marketable equity securities and equity method investments that have not been remeasured or impaired in the current period, grants receivable, reverse repurchase agreements with original maturities greater than three months, and issued debt. We classify the fair value of grants receivable and reverse repurchase agreements with original maturities greater than three months as Level 2. The estimated fair value of these financial instruments approximates their carrying value. The aggregate carrying value of grants receivable as of September 30, 2023 was $833 million (the aggregate carrying value as of December 31, 2022 was $437 million). We have no reverse repurchase agreements with original maturities greater than three months as of September 30, 2023 (the aggregate carrying value as of December 31, 2022 was $400 million).

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Note 12 : Derivative Financial Instruments Volume of Derivative Activity Total gross notional amounts for outstanding derivatives (recorded at fair value) at the end of each period were as follows: (In Millions) Sep 30, 2023 Dec 31, 2022 Foreign currency contracts $ 31,291 $ 31,603 Interest rate contracts 17,920 16,011 Other 2,103 2,094 Total $ 51,314 $ 49,708 Fair Value of Derivative Instruments in the Consolidated Condensed Balance Sheets Sep 30, 2023 Dec 31, 2022 (In Millions) Assets 1 Liabilities 2 Assets 1 Liabilities 2 Derivatives designated as hedging instruments: Foreign currency contracts 3 $ 27 $ 643 $ 142 $ 290 Interest rate contracts — 966 — 777 Total derivatives designated as hedging instruments $ 27 $ 1,609 $ 142 $ 1,067 Derivatives not designated as hedging instruments: Foreign currency contracts 3 $ 601 $ 102 $ 866 $ 194 Interest rate contracts 386 4 266 12 Equity contracts 131 17 — 111 Total derivatives not designated as hedging instruments $ 1,118 $ 123 $ 1,132 $ 317 Total derivatives $ 1,145 $ 1,732 $ 1,274 $ 1,384 1 Derivative assets are recorded as other assets, current and long-term. 2 Derivative liabilities are recorded as other liabilities, current and long-term. 3 A majority of these instruments mature within 12 months. Amounts Offset in the Consolidated Condensed Balance Sheets Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Sep 30, 2023 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,011 $ — $ 1,011 $ (538) $ (473) $ — Reverse repurchase agreements 2,334 — 2,334 — (2,334) — Total assets $ 3,345 $ — $ 3,345 $ (538) $ (2,807) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 1,724 $ — $ 1,724 $ (538) $ (1,085) $ 101 Total liabilities $ 1,724 $ — $ 1,724 $ (538) $ (1,085) $ 101 Dec 31, 2022 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,231 $ — $ 1,231 $ (546) $ (682) $ 3 Reverse repurchase agreements 1,701 — 1,701 — (1,701) — Total assets $ 2,932 $ — $ 2,932 $ (546) $ (2,383) $ 3 Liabilities: Derivative liabilities subject to master netting arrangements $ 1,337 $ — $ 1,337 $ (546) $ (712) $ 79 Total liabilities $ 1,337 $ — $ 1,337 $ (546) $ (712) $ 79 We obtain and secure available collateral from counterparties against obligations, including securities lending transactions and reverse repurchase agreements, when we deem it appropriate. Derivatives in Cash Flow Hedging Relationships The before-tax net gains or losses attributed to cash flow hedges recognized in other comprehensive income (loss) were $454 million net losses in the third quarter of 2023 and $646 million net losses in the first nine months of 2023 ($678 million net losses in the third quarter of 2022 and $1.6 billion net losses in the first nine months of 2022). Substantially all of our cash flow hedges were foreign currency contracts for all periods presented. During the first nine months of 2023 and 2022, the amounts excluded from effectiveness testing were insignificant. Derivatives in Fair Value Hedging Relationships The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows: Gains (Losses) on Derivatives Recognized in Consolidated Condensed Statements of Income Three Months Ended Nine Months Ended (In Millions) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Interest rate contracts $ (168) $ (589) $ (189) $ (1,536) Hedged items 168 589 189 1,536 Total $ — $ — $ — $ — The amounts recorded on the Consolidated Condensed Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows: Line Item in the Consolidated Condensed Balance Sheets in Which the Hedged Item is Included Carrying Amount of the Hedged Item Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities) (In Millions) Sep 30, 2023 Dec 31, 2022 Sep 30, 2023 Dec 31, 2022 Long-term debt $ (11,032) $ (11,221) $ 965 $ 776 The total notional amount of outstanding pay-variable, receive-fixed interest rate swaps was $12.0 billion as of September 30, 2023 and December 31, 2022. Derivatives Not Designated as Hedging Instruments The effects of derivative instruments not designated as hedging instruments on the Consolidated Condensed Statements of Income for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Location of Gains (Losses) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Foreign currency contracts Interest and other, net $ 255 $ 771 $ 467 $ 1,952 Interest rate contracts Interest and other, net 85 164 175 289 Other Various (112) (97) 103 (562) Total $ 228 $ 838 $ 745 $ 1,679

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Note 13 : Contingencies Legal Proceedings We are regularly party to various ongoing claims, litigation, and other proceedings, including those noted in this section. We have accrued a charge of $2.2 billion related to litigation involving VLSI and a charge of $401 million related to an EC-imposed fine, both as described below. Excluding the VLSI claims, management at present believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, results of operations, cash flows, or overall trends; however, legal proceedings and related government investigations are subject to inherent uncertainties, and unfavorable rulings, excessive verdicts, or other events could occur. Unfavorable resolutions could include substantial monetary damages, fines, or penalties. Certain of these outstanding matters include speculative, substantial, or indeterminate monetary awards. In addition, in matters for which injunctive relief or other conduct remedies are sought, unfavorable resolutions could include an injunction or other order prohibiting us from selling one or more products at all or in particular ways, precluding particular business practices, or requiring other remedies. An unfavorable outcome may result in a material adverse impact on our business, results of operations, financial position, and overall trends. We might also conclude that settling one or more such matters is in the best interests of our stockholders, employees, and customers, and any such settlement could include substantial payments. Unless specifically described below, we have not concluded that settlement of any of the legal proceedings noted in this section is appropriate at this time. European Commission Competition Matter In 2009, the EC found that we had used unfair business practices to persuade customers to buy microprocessors in violation of Article 82 of the EC Treaty (later renumbered Article 102) and Article 54 of the European Economic Area Agreement. In general, the EC found that we violated Article 82 by offering alleged “conditional rebates and payments” that required customers to purchase all or most of their x86 microprocessors from us and by making alleged “payments to prevent sales of specific rival products.” The EC ordered us to end the alleged infringement referred to in its decision and imposed a €1.1 billion fine, which we paid in the third quarter of 2009. We appealed the EC decision to the European Court of Justice in 2014, after the General Court (then called the Court of First Instance) rejected our appeal of the EC decision in its entirety. In September 2017, the Court of Justice sent the case back to the General Court to examine whether the rebates at issue were capable of restricting competition. In January 2022, the General Court annulled the EC’s 2009 findings against us regarding rebates, as well as the €1.1 billion fine imposed on Intel, which was returned to us in February 2022. The General Court’s January 2022 decision did not annul the EC’s 2009 finding that we made payments to prevent sales of specific rival products. In April 2022, the EC appealed the General Court’s decision to the Court of Justice. In addition, in September 2023 the EC imposed a €376 million ($401 million) fine against us based on its finding that we made payments to prevent sales of specific rival products. We plan to appeal the EC’s decision. We have accrued a charge for the fine and are unable to make a reasonable estimate of the potential loss or range of losses in excess of this amount given the procedural posture and the nature of these proceedings. In a related matter, in April 2022 we filed applications with the General Court seeking an order requiring the EC to pay us approximately €593 million in default interest on the original €1.1 billion fine that was held by the EC for 12 years, which applications have been stayed pending the EC’s appeal of the General Court’s January 2022 decision. Litigation Related to Security Vulnerabilities In June 2017, a Google research team notified Intel and other companies that it had identified security vulnerabilities, now commonly referred to as “Spectre” and “Meltdown,” that affect many types of microprocessors, including our products. As is standard when findings like these are presented, we worked together with other companies in the industry to verify the research and develop and validate software and firmware updates for impacted technologies. In January 2018, information on the security vulnerabilities was publicly reported, before software and firmware updates to address the vulnerabilities were made widely available. As of October 25, 2023, consumer class action lawsuits against us were pending in the US, Canada, and Argentina. The plaintiffs, who purport to represent various classes of purchasers of our products, generally claim to have been harmed by our actions and/or omissions in connection with the security vulnerabilities and assert a variety of common law and statutory claims seeking monetary damages and equitable relief. In the US, class action suits filed in various jurisdictions were consolidated for all pretrial proceedings in the US District Court for the District of Oregon, which entered final judgment in favor of Intel in July 2022 based on plaintiffs’ failure to plead a viable claim. Plaintiffs have appealed that decision to the Ninth Circuit Court of Appeals. In Canada, an initial status conference has not yet been scheduled in one case pending in the Superior Court of Justice of Ontario, and a stay of a second case pending in the Superior Court of Justice of Quebec is in effect. In Argentina, Intel Argentina was served with, and responded to, a class action complaint in June 2022. The Argentinian court dismissed plaintiffs’ claims for lack of standing in May 2023, and plaintiffs have appealed. Additional lawsuits and claims may be asserted seeking monetary damages or other related relief. We dispute the pending claims described above and intend to defend those lawsuits vigorously. Given the procedural posture and the nature of those cases, including that the pending proceedings are in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class or classes being certified or the ultimate size of any class or classes if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from those matters. Litigation Related to 7nm Product Delay Announcement Multiple securities class action lawsuits were filed in the US District Court for the Northern District of California against us and certain officers following our July 2020 announcement of 7nm product delays. The court consolidated the lawsuits and appointed lead plaintiffs in October 2020, and in January 2021 plaintiffs filed a consolidated complaint. Plaintiffs purport to represent all persons who purchased or otherwise acquired our common stock from October 25, 2019 through October 23, 2020, and they generally allege that defendants violated the federal securities laws by making false or misleading statements about the timeline for 7nm products. In March 2023, the court granted the defendants’ motion to dismiss the consolidated complaint, and in April 2023 entered judgment. Plaintiffs have appealed. Given the procedural posture and the nature of the case, including that it is in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class being certified or the ultimate size of any class if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from the matter. In July 2021, we introduced a new process node naming structure, and the 7nm process is now called Intel 4. Litigation Related to Patent and IP Claims We have had IP infringement lawsuits filed against us, including but not limited to those discussed below. Most involve claims that certain of our products, services, and technologies infringe others' IP rights. Adverse results in these lawsuits may include awards of substantial fines and penalties, costly royalty or licensing agreements, or orders preventing us from offering certain features, functionalities, products, or services. As a result, we may have to change our business practices, and develop non-infringing products or technologies, which could result in a loss of revenue for us and otherwise harm our business. In addition, certain agreements with our customers require us to indemnify them against certain IP infringement claims, which can increase our costs as a result of defending such claims, and may require that we pay significant damages, accept product returns, or supply our customers with non-infringing products if there were an adverse ruling in any such claims. In addition, our customers and partners may discontinue the use of our products, services, and technologies, as a result of injunctions or otherwise, which could result in loss of revenue and adversely affect our business. VLSI Technology LLC v. Intel In October 2017, VLSI Technology LLC (VLSI) filed a complaint against us in the US District Court for the Northern District of California alleging that various Intel FPGA and processor products infringe eight patents that VLSI acquired from NXP Semiconductors, N.V. (NXP). Four patents remain at issue in the case, and VLSI estimates its damages to be approximately $890 million, and seeks enhanced damages, future royalties, attorneys’ fees, costs, and interest. We filed Inter Partes Review (IPR) petitions with the Patent Trial and Appeal Board (PTAB) in 2018 challenging patentability, and the parties stipulated to stay the district court action pending the PTAB’s review. The PTAB subsequently found all claims of two patents, and some claims of two other patents, to be unpatentable. The district court lifted the stay in September 2021, and scheduled trial for March 2024 on the claims that were found patentable by the PTAB. In April 2019, VLSI filed three infringement suits against us in the US District Court for the Western District of Texas accusing various of our processors of infringement of eight additional patents it had acquired from NXP: ▪ The first Texas case went to trial in February 2021, and the jury awarded VLSI $1.5 billion for literal infringement of one patent and $675 million for infringement of another patent under the doctrine of equivalents. In April 2022, the court entered final judgment, awarding VLSI $2.2 billion in damages and approximately $162.3 million in pre-judgment and post-judgment interest. We have appealed the judgment to the Federal Circuit Court of Appeals, including the court's rejection of Intel's claim to have a license from Fortress Investment Group’s acquisition of Finjan. The Federal Circuit Court heard oral argument in October 2023. In December 2021 and January 2022 the PTAB instituted IPRs on the claims found to have been infringed in the first Texas case, and in May and June 2023 found all of those claims unpatentable; VLSI has appealed the PTAB’s decisions, and has asked to stay those appeals while the PTAB decides certain issues unrelated to the merits of the IPRs. Intel has agreed to the stay. ▪ The second Texas case went to trial in April 2021, and the jury found that we do not infringe the asserted patents. VLSI had sought approximately $3.0 billion for alleged infringement, plus enhanced damages for willful infringement. The court has not yet entered final judgment. ▪ The third Texas case went to trial in November 2022, with VLSI asserting one remaining patent. The jury found the patent valid and infringed, and awarded VLSI approximately $949 million in damages, plus interest and a running royalty. The court has not yet entered final judgment. In February 2023, we filed motions for a new trial and for judgment as a matter of law notwithstanding the verdict on various grounds. Further appeals are possible. In May 2019, VLSI filed a case in Shenzhen Intermediate People’s Court against Intel, Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. VLSI asserts one patent against certain Intel Core processors. Defendants filed an invalidation petition in October 2019 with the China National Intellectual Property Administration (CNIPA) which held a hearing in September 2021. The Shenzhen court held trial proceedings in July 2021, and September 2023. VLSI seeks an injunction as well as RMB 1.3 million in costs and expenses, but no damages. In September 2023, the CNIPA invalidated every claim of the asserted patent. In May 2019, VLSI filed a case in Shanghai Intellectual Property Court against Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. asserting one patent against certain Intel core processors. The court held a trial hearing in December 2020, where VLSI requested expenses (RMB 300 thousand) and an injunction. In December 2022, we filed a petition to invalidate the patent at issue. The court held a second trial hearing in May 2022, and in October 2023, issued a decision finding no infringement and dismissing all claims. We have accrued a charge of approximately $2.2 billion related to the VLSI litigation. While we dispute VLSI’s claims and intend to vigorously defend against them, we are unable to make a reasonable estimate of losses in excess of recorded amounts given recent developments and future proceedings. R2 Semiconductor Patent Litigation In November 2022, R2 Semiconductor, Inc. (R2) filed a lawsuit in the High Court of Justice in the UK against Intel Corporation (UK) Limited and Intel Corporation, and a lawsuit in the Dusseldorf Regional Court in Germany against Intel Deutschland GmbH and certain Intel customers. R2 asserts one European patent is infringed by Intel’s Ice Lake, Tiger Lake, Alder Lake and Ice Lake Server (Xeon) processors, and customer servers and laptops that contain those processors. R2 seeks an injunction in both actions prohibiting the sale and requiring the recall of the alleged infringing products. Intel is indemnifying its customers in the German lawsuit. Intel disputes R2’s claims and intends to defend the lawsuits vigorously. In December 2022, Intel responded in the UK action that the asserted patent is not infringed and that the patent is invalid. In April 2023, defendants filed statements of defense in the German action that the asserted patent is not infringed and that an injunction would be a disproportionate remedy. In May 2023, defendants also filed a nullity action in the German Federal Patent Court on the ground that the asserted patent is invalid. Trial is scheduled for December 2023 in the Dusseldorf Regional Court, and for April 2024 in the UK High Court of Justice. If defendants lose at trial in Germany, the Dusseldorf Regional Court could impose an injunction and recall order prohibiting sales of the accused products in Germany which could take effect immediately and remain in place unless overturned on appeal, or unless the patent is invalidated by the German Federal Patent Court. Given the procedural posture and the nature of these cases, including that there are significant factual and legal issues to be resolved and that uncertainty exists as to the scope of an injunction, if any, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from these lawsuits.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022	Sep. 30, 2023	Oct. 01, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 297	$ 1,019	$ (980)	$ 8,678

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Operating Segments (Tables)

Operating Segments (Tables)	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Net revenue and operating income (loss) for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Net revenue: Client Computing Desktop $ 2,753 $ 3,222 $ 7,002 $ 8,152 Notebook 4,503 4,408 11,806 15,118 Other 611 498 1,606 1,858 7,867 8,128 20,414 25,128 Data Center and AI 3,814 4,255 11,536 15,024 Network and Edge 1,450 2,133 4,303 6,483 Mobileye 530 450 1,442 1,304 Intel Foundry Services 311 78 661 291 All other 186 294 466 782 Total net revenue $ 14,158 $ 15,338 $ 38,822 $ 49,012 Operating income (loss): Client Computing $ 2,073 $ 1,447 $ 3,632 $ 5,045 Data Center and AI 71 (139) (608) 1,174 Network and Edge 17 197 (470) 907 Mobileye 170 142 422 480 Intel Foundry Services (86) (90) (369) (247) All other (2,253) (1,732) (5,099) (3,893) Total operating income (loss) $ (8) $ (175) $ (2,492) $ 3,466 In the second quarter of 2022, we initiated the wind-down of our Intel® Optane™ memory business, which is part of our DCAI operating segment, resulting in an inventory impairment of $559 million in Cost of sales

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended (In Millions, Except Per Share Amounts) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Net income (loss) $ 310 $ 1,019 $ (985) $ 8,678 Less: Net income (loss) attributable to non-controlling interests 13 — (5) — Net income (loss) attributable to Intel 297 1,019 (980) 8,678 Weighted average shares of common stock outstanding—basic 4,202 4,118 4,180 4,104 Dilutive effect of employee equity incentive plans 27 7 — 19 Weighted average shares of common stock outstanding—diluted 4,229 4,125 4,180 4,123 Earnings (loss) per share attributable to Intel—basic $ 0.07 $ 0.25 $ (0.23) $ 2.11 Earnings (loss) per share attributable to Intel—diluted $ 0.07 $ 0.25 $ (0.23) $ 2.10

Other Financial Statement Det_2

Other Financial Statement Details (Tables)	9 Months Ended
	Sep. 30, 2023
Other Financial Statement Details [Abstract]
Schedule of Inventory, Current [Table Text Block]	(In Millions) Sep 30, 2023 Dec 31, 2022 Raw materials $ 1,278 $ 1,517 Work in process 6,266 7,565 Finished goods 3,922 4,142 Total inventories $ 11,466 $ 13,224
Interest and Other, Net [Table Text Block]	Three Months Ended Nine Months Ended (In Millions) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Interest income $ 332 $ 170 $ 979 $ 315 Interest expense (204) (114) (611) (347) Other, net 19 82 144 1,048 Total interest and other, net $ 147 $ 138 $ 512 $ 1,016

Restructuring and Other Charg_2

Restructuring and Other Charges (Tables)	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Other Charges	Three Months Ended Nine Months Ended (In Millions) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Employee severance and benefit arrangements $ 59 $ 607 $ 191 $ 650 Litigation charges and other 757 4 854 (1,199) Asset impairment charges — 53 35 89 Total restructuring and other charges $ 816 $ 664 $ 1,080 $ (460)
Schedule of Accrued Restructuring	Restructuring activity for the 2022 Restructuring Program during the first nine months of 2023 was as follows: (In Millions) Accrued restructuring balance as of December 31, 2022 $ 873 Additional accruals 130 Adjustments 56 Cash payments (923) Accrued restructuring balance as of September 30, 2023 $ 136

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Provision for Income Tax and Effective Tax Rate	Three Months Ended Nine Months Ended (In Millions) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Income (loss) before taxes $ (52) $ (188) $ (2,026) $ 8,564 Provision for (benefit from) taxes $ (362) $ (1,207) $ (1,041) $ (114) Effective tax rate 696.2 % 642.0 % 51.4 % (1.3) %

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Investments Classified by Contractual Maturity Date [Table Text Block]	The fair value of marketable debt investments, by contractual maturity, as of September 30, 2023, was as follows: (In Millions) Fair Value Due in 1 year or less $ 11,487 Due in 1–2 years 2,249 Due in 2–5 years 6,220 Due after 5 years 417 Instruments not due at a single maturity date 1 1,814 Total $ 22,187
Investment [Table Text Block]	(In Millions) Sep 30, 2023 Dec 31, 2022 Marketable equity securities 1 $ 1,117 $ 1,341 Non-marketable equity securities 4,578 4,561 Equity method investments 5 10 Total $ 5,700 $ 5,912 1 Over 90% of our marketable equity securities are subject to trading-volume or market-based restrictions, which limit the number of shares we may sell in a specified period of time, impacting our ability to liquidate these investments. The trading volume restrictions generally apply for as long as we own more than 1% of the outstanding shares. Market-based restrictions result from the rules of the respective exchange.
Gain (Loss) on Securities [Table Text Block]	The components of gains (losses) on equity investments, net for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Ongoing mark-to-market adjustments on marketable equity securities $ (267) $ (244) $ (164) $ (883) Observable price adjustments on non-marketable equity securities 7 67 17 273 Impairment charges (53) (45) (127) (112) Sale of equity investments and other 1 122 71 228 4,804 Total gains (losses) on equity investments, net $ (191) $ (151) $ (46) $ 4,082 1 Sale of equity investments and other includes initial fair value adjustments recorded upon a security becoming marketable, realized gains (losses) on sales of non-marketable equity investments and equity method investments, and our share of equity method investee gains (losses) and distributions. Net unrealized gains and losses for our marketable and non-marketable equity securities for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Net unrealized gains (losses) recognized during the period on equity securities $ (205) $ (154) $ (64) $ (490) Less: Net (gains) losses recognized during the period on equity securities sold during the period 12 1 (15) 15 Net unrealized gains (losses) recognized during the reporting period on equity securities still held at the reporting date $ (193) $ (153) $ (79) $ (475)

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis Sep 30, 2023 Dec 31, 2022 Fair Value Measured and Recorded at Reporting Date Using Fair Value Measured and Recorded at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Cash equivalents: Corporate debt $ — $ 1,074 $ — $ 1,074 $ — $ 856 $ — $ 856 Financial institution instruments¹ 1,779 1,876 — 3,655 6,899 1,474 — 8,373 Government debt² — 49 — 49 — — — — Reverse repurchase agreements — 2,334 — 2,334 — 1,301 — 1,301 Short-term investments: Corporate debt — 6,168 — 6,168 — 5,381 — 5,381 Financial institution instruments¹ 35 4,105 — 4,140 196 4,729 — 4,925 Government debt² 50 7,051 — 7,101 48 6,840 — 6,888 Other current assets: Derivative assets 131 1,013 — 1,144 — 1,264 — 1,264 Loans receivable — 53 — 53 — 53 — 53 Marketable equity securities 1,117 — — 1,117 1,341 — — 1,341 Other long-term assets: Derivative assets — 1 — 1 — 10 — 10 Total assets measured and recorded at fair value $ 3,112 $ 23,724 $ — $ 26,836 $ 8,484 $ 21,908 $ — $ 30,392 Liabilities Other accrued liabilities: Derivative liabilities $ 17 $ 727 $ 147 $ 891 $ 111 $ 485 $ 89 $ 685 Other long-term liabilities: Derivative liabilities — 841 — 841 — 699 — 699 Total liabilities measured and recorded at fair value $ 17 $ 1,568 $ 147 $ 1,732 $ 111 $ 1,184 $ 89 $ 1,384 1 Level 1 investments consist of money market funds. Level 2 investments consist primarily of certificates of deposit, time deposits, and notes and bonds issued by financial institutions. 2 Level 1 investments consist primarily of US Treasury securities. Level 2 investments consist primarily of non-US government debt.

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2023
Derivative [Line Items]
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	Total gross notional amounts for outstanding derivatives (recorded at fair value) at the end of each period were as follows: (In Millions) Sep 30, 2023 Dec 31, 2022 Foreign currency contracts $ 31,291 $ 31,603 Interest rate contracts 17,920 16,011 Other 2,103 2,094 Total $ 51,314 $ 49,708
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Fair Value of Derivative Instruments in the Consolidated Condensed Balance Sheets Sep 30, 2023 Dec 31, 2022 (In Millions) Assets 1 Liabilities 2 Assets 1 Liabilities 2 Derivatives designated as hedging instruments: Foreign currency contracts 3 $ 27 $ 643 $ 142 $ 290 Interest rate contracts — 966 — 777 Total derivatives designated as hedging instruments $ 27 $ 1,609 $ 142 $ 1,067 Derivatives not designated as hedging instruments: Foreign currency contracts 3 $ 601 $ 102 $ 866 $ 194 Interest rate contracts 386 4 266 12 Equity contracts 131 17 — 111 Total derivatives not designated as hedging instruments $ 1,118 $ 123 $ 1,132 $ 317 Total derivatives $ 1,145 $ 1,732 $ 1,274 $ 1,384 1 Derivative assets are recorded as other assets, current and long-term. 2 Derivative liabilities are recorded as other liabilities, current and long-term. 3 A majority of these instruments mature within 12 months. The amounts recorded on the Consolidated Condensed Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows: Line Item in the Consolidated Condensed Balance Sheets in Which the Hedged Item is Included Carrying Amount of the Hedged Item Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities) (In Millions) Sep 30, 2023 Dec 31, 2022 Sep 30, 2023 Dec 31, 2022 Long-term debt $ (11,032) $ (11,221) $ 965 $ 776
Offsetting Assets [Table Text Block]	Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Sep 30, 2023 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,011 $ — $ 1,011 $ (538) $ (473) $ — Reverse repurchase agreements 2,334 — 2,334 — (2,334) — Total assets $ 3,345 $ — $ 3,345 $ (538) $ (2,807) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 1,724 $ — $ 1,724 $ (538) $ (1,085) $ 101 Total liabilities $ 1,724 $ — $ 1,724 $ (538) $ (1,085) $ 101 Dec 31, 2022 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,231 $ — $ 1,231 $ (546) $ (682) $ 3 Reverse repurchase agreements 1,701 — 1,701 — (1,701) — Total assets $ 2,932 $ — $ 2,932 $ (546) $ (2,383) $ 3 Liabilities: Derivative liabilities subject to master netting arrangements $ 1,337 $ — $ 1,337 $ (546) $ (712) $ 79 Total liabilities $ 1,337 $ — $ 1,337 $ (546) $ (712) $ 79
Offsetting Liabilities [Table Text Block]	Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Sep 30, 2023 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,011 $ — $ 1,011 $ (538) $ (473) $ — Reverse repurchase agreements 2,334 — 2,334 — (2,334) — Total assets $ 3,345 $ — $ 3,345 $ (538) $ (2,807) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 1,724 $ — $ 1,724 $ (538) $ (1,085) $ 101 Total liabilities $ 1,724 $ — $ 1,724 $ (538) $ (1,085) $ 101 Dec 31, 2022 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,231 $ — $ 1,231 $ (546) $ (682) $ 3 Reverse repurchase agreements 1,701 — 1,701 — (1,701) — Total assets $ 2,932 $ — $ 2,932 $ (546) $ (2,383) $ 3 Liabilities: Derivative liabilities subject to master netting arrangements $ 1,337 $ — $ 1,337 $ (546) $ (712) $ 79 Total liabilities $ 1,337 $ — $ 1,337 $ (546) $ (712) $ 79
Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	The effects of derivative instruments not designated as hedging instruments on the Consolidated Condensed Statements of Income for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Location of Gains (Losses) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Foreign currency contracts Interest and other, net $ 255 $ 771 $ 467 $ 1,952 Interest rate contracts Interest and other, net 85 164 175 289 Other Various (112) (97) 103 (562) Total $ 228 $ 838 $ 745 $ 1,679
Interest and other, net [Member] | Fair Value Hedging
Derivative [Line Items]
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows: Gains (Losses) on Derivatives Recognized in Consolidated Condensed Statements of Income Three Months Ended Nine Months Ended (In Millions) Sep 30, 2023 Oct 1, 2022 Sep 30, 2023 Oct 1, 2022 Interest rate contracts $ (168) $ (589) $ (189) $ (1,536) Hedged items 168 589 189 1,536 Total $ — $ — $ — $ —

Operating Segments (Details)

Operating Segments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022	Sep. 30, 2023	Oct. 01, 2022
Segment Reporting Information [Line Items]
Net revenue	$ 14,158	$ 15,338	$ 38,822	$ 49,012
Operating Income (Loss)	(8)	(175)	(2,492)	3,466
Operating Segments
Segment Reporting Information [Line Items]
Net revenue	14,158	15,338	38,822	49,012
Client Computing Group
Segment Reporting Information [Line Items]
Operating Income (Loss)	2,073	1,447	3,632	5,045
Client Computing Group | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	7,867	8,128	20,414	25,128
Client Computing Group | Desktop | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	2,753	3,222	7,002	8,152
Client Computing Group | Notebook | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	4,503	4,408	11,806	15,118
Client Computing Group | Other | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	611	498	1,606	1,858
Datacenter and AI
Segment Reporting Information [Line Items]
Operating Income (Loss)	71	(139)	(608)	1,174
Datacenter and AI | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	3,814	4,255	11,536	15,024
Network and Edge
Segment Reporting Information [Line Items]
Operating Income (Loss)	17	197	(470)	907
Network and Edge | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	1,450	2,133	4,303	6,483
Mobileye
Segment Reporting Information [Line Items]
Operating Income (Loss)	170	142	422	480
Mobileye | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	530	450	1,442	1,304
Intel Foundry Services
Segment Reporting Information [Line Items]
Operating Income (Loss)	(86)	(90)	(369)	(247)
Intel Foundry Services | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	311	78	661	291
All other
Segment Reporting Information [Line Items]
Operating Income (Loss)	(2,253)	(1,732)	(5,099)	(3,893)
All other | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	$ 186	$ 294	$ 466	$ 782

Operating Segments - Narrative

Operating Segments - Narrative (Details) $ in Millions	3 Months Ended
	Oct. 01, 2022 USD ($)
Segment Reporting Information [Line Items]
Inventory impairment charge	$ 559

Non-Controlling Interests (Deta

Non-Controlling Interests (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended				9 Months Ended		12 Months Ended
	Aug. 31, 2023	Dec. 30, 2023	Sep. 30, 2023	Jul. 01, 2023	Oct. 01, 2022	Sep. 30, 2023	Oct. 01, 2022	Dec. 31, 2022
Noncontrolling Interest [Line Items]
Assets			$ 188,837			$ 188,837		$ 182,103
Non-controlling interest			3,873			3,873		1,863
Net Income (Loss) attributable to noncontrolling interest			13		$ 0	(5)	$ 0
Proceeds from sales of subsidiary shares						2,423	$ 0
Mobileye
Noncontrolling Interest [Line Items]
Net proceeds								1,000
Semiconductor Co-Investment Program, Construction Costs | Intel and Brookfield
Noncontrolling Interest [Line Items]
Unrecognized commitment			29,000			$ 29,000
Arizona Fab
Noncontrolling Interest [Line Items]
Percentage of factory output with the right to purchase						100%
Non-controlling interest			2,000			$ 2,000		874
Net Income (Loss) attributable to noncontrolling interest			(3)			(12)
Mobileye
Noncontrolling Interest [Line Items]
Non-controlling interest			1,800			1,800		$ 1,000
Net Income (Loss) attributable to noncontrolling interest			$ (6)			$ (3)
Net proceeds				$ 1,600
Conversion of stock, shares converted (in shares)				38,500,000
Conversion of stock, shares converted, percentage of outstanding shares				0.05
Shares issued per share (in dollars per share)				$ 42
Non-controlling interest percent held by parent			88%			88%		94%
Mobileye | Common Stock and Capital in Excess of Par Value
Noncontrolling Interest [Line Items]
Increase from subsidiary equity issuance				$ 663
IMS
Noncontrolling Interest [Line Items]
Non-controlling interest			$ 109			$ 109
Net Income (Loss) attributable to noncontrolling interest			(10)			(10)
Ownership percentage sold	20%
Proceeds from sales of subsidiary shares	$ 849
IMS | Forecast
Noncontrolling Interest [Line Items]
Ownership percentage sold		12.50%
IMS | TSMC | Forecast
Noncontrolling Interest [Line Items]
Ownership percentage sold		10%
IMS | Common Stock and Capital in Excess of Par Value
Noncontrolling Interest [Line Items]
Increase from subsidiary equity issuance	$ 591
Variable Interest Entity, Primary Beneficiary | Asset Pledged as Collateral
Noncontrolling Interest [Line Items]
Assets			$ 4,000			$ 4,000		$ 1,800
Variable Interest Entity, Primary Beneficiary | Arizona Fab
Noncontrolling Interest [Line Items]
Interest in variable interest entity						51%
Variable Interest Entity, Not Primary Beneficiary | Arizona Fab
Noncontrolling Interest [Line Items]
Interest in variable interest entity						49%

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022	Sep. 30, 2023	Oct. 01, 2022
Earnings Per Share [Abstract]
Net income (loss)	$ 310	$ 1,019	$ (985)	$ 8,678
Less: Net income (loss) attributable to non-controlling interests	13	0	(5)	0
Net income (loss) attributable to Intel	$ 297	$ 1,019	$ (980)	$ 8,678
Weighted average shares of common stock outstanding—basic	4,202	4,118	4,180	4,104
Dilutive effect of employee equity incentive plans (shares)	27	7	0	19
Weighted average shares of common stock outstanding—diluted	4,229	4,125	4,180	4,123
Earnings per share - Basic (in dollars per share)	$ 0.07	$ 0.25	$ (0.23)	$ 2.11
Earnings per share - Diluted (in dollars per share)	$ 0.07	$ 0.25	$ (0.23)	$ 2.10

Other Financial Statement Det_3

Other Financial Statement Details - Accounts Receivable (Details) $ in Billions	9 Months Ended
	Sep. 30, 2023 USD ($)
Other Financial Statement Details [Abstract]
Accounts receivable sold	$ 1.5

Other Financial Statement Det_4

Other Financial Statement Details - Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Other Financial Statement Details [Abstract]
Raw materials	$ 1,278	$ 1,517
Work in process	6,266	7,565
Finished goods	3,922	4,142
Total inventories	$ 11,466	$ 13,224

Other Financial Statement Det_5

Other Financial Statement Details - Other Accrued Liabilities (Details) - USD ($) $ in Billions	Sep. 30, 2023	Dec. 31, 2022
Other Financial Statement Details [Abstract]
Deferred compensation	$ 2.6	$ 2.4

Other Financial Statement Det_6

Other Financial Statement Details - Interest and Other, Net (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
	Dec. 29, 2021	Sep. 30, 2023	Oct. 01, 2022	Sep. 30, 2023	Oct. 01, 2022
Other Financial Statement Details [Abstract]
Interest income		$ 332	$ 170	$ 979	$ 315
Interest expense		(204)	(114)	(611)	(347)
Other, net		19	82	144	1,048
Total interest and other, net		147	138	512	1,016
Interest Costs Capitalized		$ (395)	(220)	(1,100)	(516)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gains on divestitures				$ 0	$ 1,072
NAND Memory Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gains on divestitures	$ 1,000		$ 1,000

Other Financial Statement Det_7

Other Financial Statement Details - Property, Plant and Equipment (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022	Sep. 30, 2023	Oct. 01, 2022	Jan. 01, 2023	Dec. 31, 2022
Change in Accounting Estimate [Line Items]
Increase to gross margin	$ 6,018	$ 6,535	$ 14,664	$ 21,366
Decrease in R&D expenses	(3,870)	$ (4,302)	(12,059)	$ (13,064)
Decrease in ending inventory	(11,466)		(11,466)			$ (13,224)
Estimated useful life
Change in Accounting Estimate [Line Items]
Increase to gross margin	690		1,600
Decrease in R&D expenses	110		320
Decrease in ending inventory	$ 1,200		$ 1,200
Certain production machinery and equipment
Change in Accounting Estimate [Line Items]
Useful life					8 years	5 years

Restructuring and Other Charg_3

Restructuring and Other Charges - Components (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022	Sep. 30, 2023	Oct. 01, 2022
Restructuring and Related Activities [Abstract]
Employee severance and benefit arrangements	$ 59	$ 607	$ 191	$ 650
Litigation charges and other	757	4	854	(1,199)
Asset impairment charges	0	53	35	89
Restructuring and other charges	$ 816	$ 664	$ 1,080	$ (460)

Restructuring and Other Charg_4

Restructuring and Other Charges - Narrative (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022	Apr. 02, 2022	Sep. 30, 2023	Oct. 01, 2022
Loss Contingencies [Line Items]
Charge (benefit) recorded in litigation charges and other	$ 757	$ 4		$ 854	$ (1,199)
Tower
Loss Contingencies [Line Items]
Charge (benefit) recorded in litigation charges and other	353
Total enterprise value			$ 5,400
2022 Restructuring Program
Loss Contingencies [Line Items]
Cumulative restructuring cost	1,200			$ 1,200
EC Fine
Loss Contingencies [Line Items]
Charge (benefit) recorded in litigation charges and other	$ 401		$ (1,200)

Restructuring and Other Charg_5

Restructuring and Other Charges - Accrued Restructuring (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022
Restructuring Cost and Reserve [Line Items]
Additional accruals	$ 718	$ 665
2022 Restructuring Program
Restructuring Cost and Reserve [Line Items]
Accrued restructuring, beginning balance	873
Additional accruals	130
Adjustments	56
Cash payments	(923)
Accrued restructuring, ending balance	$ 136

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022	Sep. 30, 2023	Oct. 01, 2022
Income Tax Disclosure [Abstract]
Income (loss) before taxes	$ (52)	$ (188)	$ (2,026)	$ 8,564
Provision for (benefit from) taxes	$ (362)	$ (1,207)	$ (1,041)	$ (114)
Effective tax rate	696.20%	642%	51.40%	(1.30%)

Investments - Short-term Invest

Investments - Short-term Investments (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022	Sep. 30, 2023	Oct. 01, 2022	Dec. 31, 2022
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt Securities, Realized Gain (Loss)	$ 329,000,000	$ 861,000,000	$ (336,000,000)	$ 1,800,000,000
Debt Securities, Available-for-sale, Amortized Cost	6,100,000,000		6,100,000,000		$ 10,200,000,000
Available-for-sale Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Derivative, Amount of Hedged Item	16,100,000,000		16,100,000,000		$ 16,200,000,000
Unrealized Gain (Loss) on Derivatives	$ 320,000,000	$ 916,000,000	$ 354,000,000	$ 1,800,000,000

Investments - Available-for-Sal

Investments - Available-for-Sale Debt Investments (Details) $ in Millions	Sep. 30, 2023 USD ($)
Investments, Debt and Equity Securities [Abstract]
Due in 1 year or less	$ 11,487
Due in 1–2 years	2,249
Due in 2–5 years	6,220
Due after 5 years	417
Instruments not due at a single maturity date	1,814
Debt Securities, Available-for-Sale, Total	$ 22,187

Investments - Equity Investment

Investments - Equity Investments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022	Sep. 30, 2023	Oct. 01, 2022	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	$ 1,117		$ 1,117		$ 1,341
Cost Method Investments	4,578		4,578		4,561
Equity Method Investments	5		5		10
Equity Investments	5,700		$ 5,700		$ 5,912
Marketable equity securities subject to trading-volume or market-based restrictions			90%
Marketable equity securities threshold percentage of shares owned resulting in trading volume restrictions			1%
Mark to market on marketable equity securities1	(267)	$ (244)	$ (164)	$ (883)
Observable price adjustments on non-marketable	7	67	17	273
Impairments	(53)	(45)	(127)	(112)
Other Net Equity Investments	122	71	228	4,804
Gain (Loss) on Investments	(191)	(151)	(46)	4,082
Net unrealized gains (losses) recognized during the period on equity securities	(205)	(154)	(64)	(490)
Less: Net (gains) losses recognized during the period on equity securities sold during the period	12	1	(15)	15
Net unrealized gains (losses) recognized during the reporting period on equity securities still held at the reporting date	$ (193)	$ (153)	$ (79)	$ (475)

Investments - Equity Investme_2

Investments - Equity Investments, Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022	Sep. 30, 2023	Oct. 01, 2022
Schedule of Equity Method Investments [Line Items]
Special dividend recognized in sale of equity investments and other	$ 122	$ 71	$ 228	$ 4,804
McAfee
Schedule of Equity Method Investments [Line Items]
Gain on sale of equity method investment	$ 4,600

Investments - Bejing Unisoc Tec

Investments - Bejing Unisoc Technology (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022	Sep. 30, 2023	Oct. 01, 2022
Schedule of Investments [Line Items]
Gains (losses) on equity investments, net	$ (191)	$ (151)	$ (46)	$ 4,082

Acquisitions and Divestitures (

Acquisitions and Divestitures (Details) - USD ($) $ in Millions			3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 29, 2021	Oct. 19, 2020	Sep. 30, 2023	Oct. 01, 2022	Sep. 30, 2023	Oct. 01, 2022	Dec. 30, 2023	Dec. 31, 2022	Oct. 31, 2020
Business Acquisition [Line Items]
Proceeds from divestiture					$ 0	$ 6,579
Gains on divestitures					0	1,072
Income Tax Expense (Benefit)			$ (362)	$ (1,207)	(1,041)	$ (114)
Goodwill			27,591		27,591			$ 27,591
Receivable recorded in other current assets			4,472		4,472			$ 4,712
Affiliated Entity | NAND Memory Business Divestiture
Business Acquisition [Line Items]
Receivable recorded in other current assets			204		204
NAND Memory Business
Business Acquisition [Line Items]
Consideration transferred for divestiture of business		$ 9,000
Proceeds from divestiture	$ 7,000
Gains on divestitures	1,000			$ 1,000
Income Tax Expense (Benefit)	$ 495
Maximum exposure annually									$ 500
Maximum exposure									$ 1,500
Nontrade Receivables, Noncurrent			$ 1,900		$ 1,900
Forecast | Affiliated Entity | NAND Memory Business Divestiture
Business Acquisition [Line Items]
Quarterly expense reimbursement							$ 32

Borrowings - Narrative (Details

Borrowings - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Jul. 01, 2023	Sep. 30, 2023	Oct. 01, 2022	Dec. 31, 2022
Debt Instrument [Line Items]
Commercial paper settled in cash	$ 3,900,000,000		$ 3,944,000,000	$ 0
Commercial paper outstanding					$ 3,900,000,000
Repayments of Long-term Debt			423,000,000	3,088,000,000
Proceeds from issuance of debt			11,391,000,000	$ 6,103,000,000
Commercial Paper
Debt Instrument [Line Items]
Maximum borrowing capacity	10,000,000,000		10,000,000,000
Arizona and Oregon bonds
Debt Instrument [Line Items]
Face amount of debt	$ 423,000,000		$ 423,000,000
Arizona and Oregon bonds | Minimum
Debt Instrument [Line Items]
Interest rate	3.80%		3.80%
Arizona and Oregon bonds | Maximum
Debt Instrument [Line Items]
Interest rate	4.10%		4.10%
Variable Rate Revolving Credit Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Term of debt		5 years
Variable rate revolving credit facility		$ 5,000,000,000
Senior Notes
Debt Instrument [Line Items]
Face amount of debt		$ 11,000,000,000
Line of Credit | Credit Facility Agreement
Debt Instrument [Line Items]
Term of debt		364 days
Maximum borrowing capacity		$ 5,000,000,000

Fair Value (Detail)

Fair Value (Detail) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	$ 2,334	$ 1,701
Derivative assets, Fair Value Disclosure	1,011	1,231
Derivative liabilities, Fair Value Disclosure	1,724	1,337
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	26,836	30,392
Liabilities, Fair Value Disclosure	1,732	1,384
Fair Value, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Grants & loans Receivable, Reverse repurchase agreements, CV	833	437
Short-term and Long-term Debt, Fair Value	43,500	34,300
Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,117	1,341
Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	2,334	1,301
Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,074	856
Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	3,655	8,373
Cash Equivalents [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	49	0
Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	6,168	5,381
Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	4,140	4,925
Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	7,101	6,888
Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	1,144	1,264
Loans receivable, Fair Value Disclosure	53	53
Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	1	10
Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	891	685
Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	841	699
Level 1 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	3,112	8,484
Liabilities, Fair Value Disclosure	17	111
Level 1 [Member] | Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,117	1,341
Level 1 [Member] | Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	0	0
Level 1 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,779	6,899
Level 1 [Member] | Cash Equivalents [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	35	196
Level 1 [Member] | Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	50	48
Level 1 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	131	0
Loans receivable, Fair Value Disclosure	0	0
Level 1 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	0	0
Level 1 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	17	111
Level 1 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	0	0
Level 2 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	23,724	21,908
Liabilities, Fair Value Disclosure	1,568	1,184
Level 2 [Member] | Fair Value, Nonrecurring [Member] | Reported Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements		400
Level 2 [Member] | Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 2 [Member] | Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	2,334	1,301
Level 2 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,074	856
Level 2 [Member] | Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,876	1,474
Level 2 [Member] | Cash Equivalents [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	49	0
Level 2 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	6,168	5,381
Level 2 [Member] | Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	4,105	4,729
Level 2 [Member] | Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	7,051	6,840
Level 2 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	1,013	1,264
Loans receivable, Fair Value Disclosure	53	53
Level 2 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	1	10
Level 2 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	727	485
Level 2 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	841	699
Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	0	0
Liabilities, Fair Value Disclosure	147	89
Level 3 [Member] | Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	0	0
Level 3 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Cash Equivalents [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	0	0
Loans receivable, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	0	0
Level 3 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	147	89
Level 3 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	$ 0	$ 0

Derivative Financial Instrume_3

Derivative Financial Instruments (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022	Jul. 01, 2023	Sep. 30, 2023	Oct. 01, 2022	Dec. 31, 2022
Notional Disclosures [Abstract]
Notional amount	$ 51,314			$ 51,314		$ 49,708
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	1,011			1,011		1,231
Derivative Assets Subject to Master Netting Arrangements, Gross Amounts Offset in the Balance Sheet	0			0		0
Derivative Assets Subject to Master Netting Arrangements, Net Amount Presented in the Balance Sheet	1,011			1,011		1,231
Derivative Assets, Financial Instruments Not Offset in the Balance Sheet	(538)			(538)		(546)
Derivative Assets, Cash Collateral Not Offset in the Balance Sheet	(473)			(473)		(682)
Derivative Assets Subject to Master Netting Arrangements, Net Amount	0			0		3
Reverse Repurchase Agreements, Gross Amounts Recognized	2,334			2,334		1,701
Reverse Repurchase Agreements, Gross Amounts Offset In The Balance Sheet	0			0		0
Reverse Repurchase Agreements, Net Amount Presented in the Balance Sheet	2,334			2,334		1,701
Reverse Repurchase Agreements, Financial Instruments Not Offset in the Balance Sheet	0			0		0
Reverse Repurchase Agreements, Cash Collateral Not Offset in the Balance Sheet	(2,334)			(2,334)		(1,701)
Reverse Repurchase Agreements, Net Amount	0			0		0
Total Assets, Gross Amounts Recognized	3,345			3,345		2,932
Total Assets, Gross Amounts Offset in the Balance Sheet	0			0		0
Total Assets, Net Amounts Presented in the Balance Sheet	3,345			3,345		2,932
Total Assets, Financial Instruments, Not Offset in the Balance Sheet	(538)			(538)		(546)
Total Assets, Cash and Non Cash Collateral, Not Offset in the Balance Sheet	(2,807)			(2,807)		(2,383)
Total Assets, Net Amount	0			0		3
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	1,724			1,724		1,337
Derivative Liabilities Subject to Master Netting Arrangements, Gross Amounts Offset in the Balance Sheet	0			0		0
Derivative Liabilities Subject to Master Netting Arrangements, Net Amount Presented in the Balance Sheet	1,724			1,724		1,337
Derivative Liabilities, Financial Instruments Not Offset in the Balance Sheet	(538)			(538)		(546)
Derivative Liabilities, Cash Collateral Not Offset in the Balance Sheet	(1,085)			(1,085)		(712)
Derivative Liabilities Subject to Master Netting Arrangements, Net Amount	101			101		79
Effect of Fair Value Hedges on Results of Operations [Abstract]
Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge	168	$ 589		189	$ 1,536
Net Change In Unrealized Gain (Loss) Recognized In Income Statement On Fair Value Hedging Instruments And On Hedged Item In Fair Value Hedge	0	0		0	0
Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	1,145			1,145		1,274
Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	1,732			1,732		1,384
Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	27			27		142
Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	1,609			1,609		1,067
Not Designated as Hedging Instrument [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	228	838		745	1,679
Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	1,118			1,118		1,132
Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	123			123		317
Foreign currency contracts
Notional Disclosures [Abstract]
Notional amount	31,291			31,291		31,603
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net [Abstract]
Before-tax net gains (losses) attributed to cash flow hedges, recognized in other comprehensive income (loss)	(454)	(678)		(646)	(1,600)
Foreign currency contracts | Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	27			27		142
Foreign currency contracts | Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	643			643		290
Foreign currency contracts | Not Designated as Hedging Instrument [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	255	771		467	1,952
Foreign currency contracts | Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	601			601		866
Foreign currency contracts | Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	102			102		194
Interest rate contracts
Notional Disclosures [Abstract]
Notional amount	17,920			17,920		16,011
Effect of Fair Value Hedges on Results of Operations [Abstract]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	(168)	(589)		(189)	(1,536)
Interest rate contracts | Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	0			0		0
Interest rate contracts | Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	966			966		777
Interest rate contracts | Not Designated as Hedging Instrument [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	85	164		175	289
Interest rate contracts | Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	386			386		266
Interest rate contracts | Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	4			4		12
Other
Notional Disclosures [Abstract]
Notional amount	2,103			2,103		2,094
Other | Not Designated as Hedging Instrument [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	(112)	$ (97)		103	$ (562)
Other | Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	131			131		0
Other | Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	17			17		111
Interest Rate Swap | Long-term Debt | Fair Value Hedging
Derivative [Line Items]
Derivative, Amount of Hedged Item	12,000			12,000
Derivative, Fair Value, Net	$ (11,032)			(11,032)		$ (11,221)
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives			$ 776	$ 965

Contingencies (Detail)

Contingencies (Detail) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Oct. 01, 2022
Loss Contingencies [Line Items]
Finance lease prepayments	$ 96	$ 341